A second prostate-specific membrane antigen (PSMA) PET scan changed treatment plans for nearly half of patients whose first scan was negative, according to new research published in the July issue of The Journal of Nuclear Medicine. Findings from the repeat PSMA scans, which included both local and distant disease, resulted in a change in management for nearly 50% of these patients.
This article was originally published by MedicalXpress. For more details, images, and references:
Read Full Original Article ↗